Trastuzumab-associated Posterior Reversible Encephalopathy Syndrome

  • Abughanimeh O
  • Abu Ghanimeh M
  • Qasrawi A
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome that presents with neurological manifestations, including seizures, headache, or confusion, and is associated with posterior cerebral white matter edema on imaging. PRES is typically a benign and reversible condition. However, PRES can be fatal or associated with permanent deficits. Numerous conditions are associated with PRES, including hypertensive encephalopathy, renal diseases, and cytotoxic or immunosuppressant drugs. Recently, many case reports described the association between PRES and chemotherapeutic agents. However, trastuzumab-associated PRES is rarely reported. Herein, we report a case of a 51-year-old female with a history of metastatic gastric cancer who developed seizures while being treated with trastuzumab, and neuroimaging confirmed the diagnosis of PRES.

Cite

CITATION STYLE

APA

Abughanimeh, O., Abu Ghanimeh, M., Qasrawi, A., Al Momani, L., & Madhusudhana, S. (2018). Trastuzumab-associated Posterior Reversible Encephalopathy Syndrome. Cureus. https://doi.org/10.7759/cureus.2686

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free